These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9286411)

  • 1. In vitro priming to tumor-associated proteins.
    Hand SL; Bernhard H; Huseby ES; Rubin WD; Disis ML; Cheever MA
    Adv Exp Med Biol; 1997; 417():503-9. PubMed ID: 9286411
    [No Abstract]   [Full Text] [Related]  

  • 2. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.
    Chapatte L; Ayyoub M; Morel S; Peitrequin AL; Lévy N; Servis C; Van den Eynde BJ; Valmori D; Lévy F
    Cancer Res; 2006 May; 66(10):5461-8. PubMed ID: 16707475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
    Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
    Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the dendritic cell: the key to immunotherapy in cancer?
    Faith A; Hawrylowicz CM
    Clin Exp Immunol; 2005 Mar; 139(3):395-7. PubMed ID: 15730383
    [No Abstract]   [Full Text] [Related]  

  • 5. Dendritic cells and immunotherapy for malignant disease.
    Reid DC
    Br J Haematol; 2001 Mar; 112(4):874-87. PubMed ID: 11298582
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor reactive T cells get a boost.
    Pardoll DM
    Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
    [No Abstract]   [Full Text] [Related]  

  • 7. Dendritic cells: a journey from laboratory to clinic.
    Cerundolo V; Hermans IF; Salio M
    Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398
    [No Abstract]   [Full Text] [Related]  

  • 8. Current developments of immunotherapy in the clinic.
    Antonia S; Mulé JJ; Weber JS
    Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing T-cell expansion: have we reached the limit?
    Melenhorst JJ
    Cytotherapy; 2009; 11(7):813-4. PubMed ID: 19903094
    [No Abstract]   [Full Text] [Related]  

  • 10. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
    Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
    Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
    Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V
    Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
    J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor cellular immunotherapy: the breakthrough of dendritic cells].
    Angevin E; André F; Zitvogel L
    Bull Cancer; 2000 Jan; 87(1):107-15. PubMed ID: 10673639
    [No Abstract]   [Full Text] [Related]  

  • 14. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell based therapy of cancer.
    Lotze MT; Shurin M; Davis I; Amoscato A; Storkus WJ
    Adv Exp Med Biol; 1997; 417():551-69. PubMed ID: 9286419
    [No Abstract]   [Full Text] [Related]  

  • 20. Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy.
    Vavrova K; Vrabcova P; Filipp D; Bartunkova J; Horvath R
    Med Oncol; 2016 Dec; 33(12):136. PubMed ID: 27812850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.